India to get treatment for Hepatitis C

The drug called Epclusa which is developed to treat all genotypes of the Hepatitis C virus by Gilead Sciences, this is the latest beakthrough treatment for deadly Hepatitis C virus. This is approved by the US Food and Drug Administration (FDA).

The deadly Hepatitis C virus affects as many as150 million people worldwide and possibly 12 million in India.This pan-genotypic treatment does not require gene-type testing, eliminating the need for costly gene-type diagnostics, allowing doctors and specialists the ability to prescribe the medicine to anyone who tests positive for Hepatitis C, by taking one pill a day for 8-12 weeks before a cure is achieved.

As part of its effort to make it an affordable treatment, Gilead Sciences, together with its 11 partners in India, are pioneering a Voluntary Licensing model that transfers technology and Intellectual Property for latest treatments and cures for viral Hepatitis and HIV. Gilead, in 2014, licensed its newly-approved HCV regimens to 11 of India's pharmaceutical companies, including the prospective Epclusa, which had not yet been cleared by the US FDA.

Because of India's capabilities in generic manufacturing, where quality and low cost co-exist hand in hand, Gilead Sciences recognized that to expand patient access and to deploy these life-saving cures to low income countries around the world to the patients who need treatment most.
 

To know more about the latest update on this treatment protocol and treating centers offering the same as well as for getting your reports reviewed, post a query